May 11, 2020 / 12:39 PM / 25 days ago

BRIEF-Galectin Therapeutics Says Nash-Rx Clinical Trial Protocol Filed With FDA First Patient Currently Expected To Be Enrolled In Q2 2020

May 11 (Reuters) - Galectin Therapeutics Inc:

* GALECTIN THERAPEUTICS INC - NASH-RX CLINICAL TRIAL PROTOCOL FILED WITH FDA; FIRST PATIENT CURRENTLY EXPECTED TO BE ENROLLED IN Q2 2020

* GALECTIN THERAPEUTICS INC QTRLY LOSS PER SHARE $0.06

* GALECTIN THERAPEUTICS INC - EXPECTS THAT IT WILL REQUIRE MORE CASH TO FUND OPERATIONS AFTER SEPTEMBER 30, 2021

* GALECTIN THERAPEUTICS INC - BELIEVES IT WILL BE ABLE TO OBTAIN ADDITIONAL FINANCING AS NEEDED

* GALECTIN THERAPEUTICS INC - FILED A NEW FORM S-3 WHICH REPLACES CO'S EXISTING SHELF REGISTRATION STATEMENT, WHICH EXPIRES ON JUNE 1, 2020 Source: bit.ly/3dBwnPS Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below